These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15982779)

  • 1. Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared.
    Cairns J
    Health Policy; 2006 Apr; 76(2):134-43. PubMed ID: 15982779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Working with NICE.
    Adams C
    J Fam Health Care; 2007; 17(4):113-4. PubMed ID: 17824208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Has NICE been nice to cancer?
    Summerhayes M; Catchpole P
    Eur J Cancer; 2006 Nov; 42(17):2881-6. PubMed ID: 17070032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service?
    Pearson S; Littlejohns P
    J Health Serv Res Policy; 2007 Jul; 12(3):160-5. PubMed ID: 17716419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Clinical Guideline Centre cost-effectiveness assessment for the National Institute for Health and Clinical Excellence.
    Wonderling D; Sawyer L; Fenu E; Lovibond K; Laramée P
    Ann Intern Med; 2011 Jun; 154(11):758-65. PubMed ID: 21646559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Scottish Programme for Clinical Effectiveness in Reproductive Health (SPCERH): lessons from a three-year programme.
    Penney G; Calder A
    Health Bull (Edinb); 2000 Jul; 58(4):261-6. PubMed ID: 12813805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis against infective endocarditis for dental procedures--summary of the NICE guideline.
    Wray D; Ruiz F; Richey R; Stokes T;
    Br Dent J; 2008 May; 204(10):555-7. PubMed ID: 18500298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NICE's use of cost effectiveness as an exemplar of a deliberative process.
    Culyer AJ
    Health Econ Policy Law; 2006 Jul; 1(Pt 3):299-318. PubMed ID: 18634698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A guide to health economic evaluations.
    Drug Ther Bull; 2010 Sep; 48(9):105-8. PubMed ID: 20810710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NICE at 10 years: new challenges ahead.
    Littlejohns P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):151-6. PubMed ID: 19402803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
    Dietrich ES
    Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based child health: SIGN and NICE.
    Kelnar CJ
    Arch Dis Child Educ Pract Ed; 2008 Dec; 93(6):190-8. PubMed ID: 19028929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales.
    Trowman R; Chung H; Longson C; Littlejohns P; Clark P
    Clin Cancer Res; 2011 Aug; 17(15):4930-5. PubMed ID: 21791636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National Services--the role of the National Services Division of the Common Services Agency in commissioning specialist services on behalf of the NHS in Scotland.
    Bryson A
    Health Bull (Edinb); 2000 Sep; 58(5):363-71. PubMed ID: 12813788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.
    Varnava A; Bracchi R; Samuels K; Hughes DA; Routledge PA
    Pharmacoeconomics; 2018 May; 36(5):613-624. PubMed ID: 29520603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meeting the NICE requirements: a Markov model approach.
    Mauskopf J
    Value Health; 2000; 3(4):287-93. PubMed ID: 16464193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management, part I: introduction and general considerations.
    Manchikanti L
    Pain Physician; 2008; 11(2):161-86. PubMed ID: 18354710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.